538 related articles for article (PubMed ID: 17707884)
21. The diagnosis and management of polycythemia vera, essential thrombocythemia, and primary myelofibrosis in the JAK2 V617F era.
Zhan H; Spivak JL
Clin Adv Hematol Oncol; 2009 May; 7(5):334-42. PubMed ID: 19521323
[TBL] [Abstract][Full Text] [Related]
22. Rapid real-time PCR assay for detection of MPL W515L mutation in patients with chronic myeloproliferative disorders.
Ghaderi M; Strömberg O; Porwit A
Int J Lab Hematol; 2010 Feb; 32(1 Pt 2):122-6. PubMed ID: 19016916
[TBL] [Abstract][Full Text] [Related]
23. A study of JAK2 (V617F) gene mutation in patients with chronic myeloproliferative disorders.
Hamidah NH; Farisah NR; Azlinda AB; Wong FL; Das S; Fadillah SA; Ainoon O
Clin Ter; 2012; 163(2):109-13. PubMed ID: 22555824
[TBL] [Abstract][Full Text] [Related]
24. A new MALDI-TOF-based assay for monitoring JAK2 V617F mutation level in patients undergoing allogeneic stem cell transplantation (allo SCT) for classic myeloproliferative disorders (MPD).
Koren-Michowitz M; Shimoni A; Vivante A; Trakhtenbrot L; Rechavi G; Amariglio N; Loewenthal R; Nagler A; Cohen Y
Leuk Res; 2008 Mar; 32(3):421-7. PubMed ID: 17698191
[TBL] [Abstract][Full Text] [Related]
25. Absence of the V617F JAK2 mutation in the lymphoid compartment in a patient with essential thrombocythemia and B-chronic lymphocytic leukemia and in two relatives with lymphoproliferative disorders.
Musolino C; Allegra A; Penna G; Centorrino R; Cuzzola M; D'Angelo A; Iacopino P; Alonci A
Acta Haematol; 2009; 122(1):46-9. PubMed ID: 19816006
[TBL] [Abstract][Full Text] [Related]
26. A patient with a 20-year lag phase between JAK2-V617F+ myeloproliferation and NPM1-mutated AML arguing against a common origin of disease.
Roug AS; Nyvold CG; Juhl-Christensen C; Christensen M; Schnittger S; Hokland P
Eur J Haematol; 2011 Nov; 87(5):461-3. PubMed ID: 21689158
[TBL] [Abstract][Full Text] [Related]
27. A simple, rapid, and sensitive method for the detection of the JAK2 V617F mutation.
Tan AY; Westerman DA; Dobrovic A
Am J Clin Pathol; 2007 Jun; 127(6):977-81. PubMed ID: 17509995
[TBL] [Abstract][Full Text] [Related]
28. Diagnostic refinement of chronic myeloproliferative disorders and thrombocytoses of unknown origin by multiple RT-PCR and capillary electrophoresis of BCR-ABL rearrangements and JAK2 (V617F) mutation.
Ammatuna E; Ottone T; Zaza S; Lavorgna S; Grillo R; Curzi P; Panetta P; Federici G; Amadori S; Lo-Coco F
Ann Hematol; 2007 May; 86(5):355-61. PubMed ID: 17285276
[TBL] [Abstract][Full Text] [Related]
29. Role of the JAK2 mutation in the diagnosis of chronic myeloproliferative disorders in splanchnic vein thrombosis.
Primignani M; Barosi G; Bergamaschi G; Gianelli U; Fabris F; Reati R; Dell'Era A; Bucciarelli P; Mannucci PM
Hepatology; 2006 Dec; 44(6):1528-34. PubMed ID: 17133457
[TBL] [Abstract][Full Text] [Related]
30. The Janus Kinase 2 (JAK2) V617F mutation in hematological malignancies in México.
Ruiz-Argüelles GJ; Garcés-Eisele J; Reyes-Núñez V; Ruiz-Delgado GJ; Navarro-Vázquez M; González-Carrillo ML
Rev Invest Clin; 2006; 58(5):458-61. PubMed ID: 17408106
[TBL] [Abstract][Full Text] [Related]
31. Clinical performance of JAK2 V617F mutation detection assays in a molecular diagnostics laboratory: evaluation of screening and quantitation methods.
Cankovic M; Whiteley L; Hawley RC; Zarbo RJ; Chitale D
Am J Clin Pathol; 2009 Nov; 132(5):713-21. PubMed ID: 19846812
[TBL] [Abstract][Full Text] [Related]
32. Infrequent hypermethylation of WIF-1 promoter in BCR/ABL-negative myeloproliferative disorders.
Suzuki R; Onizuka M; Kojima M; Shimada M; Tsuboi K; Ogawa Y; Kawada H; Ando K
Tokai J Exp Clin Med; 2007 Dec; 32(4):131-5. PubMed ID: 21318952
[TBL] [Abstract][Full Text] [Related]
33. JAK2 mutation in a patient with CLL with coexistent myeloproliferative neoplasm (MPN).
Kodali S; Chen C; Rathnasabapathy C; Wang JC
Leuk Res; 2009 Dec; 33(12):e236-9. PubMed ID: 19625083
[TBL] [Abstract][Full Text] [Related]
34. Diagnostic value of JAK2 V617F somatic mutation for myeloproliferative cancer in 49 488 individuals from the general population.
Nielsen C; Birgens HS; Nordestgaard BG; Bojesen SE
Br J Haematol; 2013 Jan; 160(1):70-9. PubMed ID: 23116358
[TBL] [Abstract][Full Text] [Related]
35. The JAK2(V617F) tyrosine kinase mutation identifies clinically latent myeloproliferative disorders in patients presenting with hepatic or portal vein thrombosis.
Goulding C; Uttenthal B; Foroni L; Duke V; Traore A; Kottaridis P; Hoffbrand AV; Patch D; McNamara C
Int J Lab Hematol; 2008 Oct; 30(5):415-9. PubMed ID: 19046316
[TBL] [Abstract][Full Text] [Related]
36. Janus kinase 2 mutations in Philadelphia negative chronic myeloproliferative disorders: clinical implications.
Panani AD
Cancer Lett; 2009 Oct; 284(1):7-14. PubMed ID: 19269737
[TBL] [Abstract][Full Text] [Related]
37. Amplification refractory mutation system, a highly sensitive and simple polymerase chain reaction assay, for the detection of JAK2 V617F mutation in chronic myeloproliferative disorders.
Chen Q; Lu P; Jones AV; Cross NC; Silver RT; Wang YL
J Mol Diagn; 2007 Apr; 9(2):272-6. PubMed ID: 17384221
[TBL] [Abstract][Full Text] [Related]
38. A new potential oncogenic mutation in the FERM domain of JAK2 in BCR/ABL1-negative and V617F-negative chronic myeloproliferative neoplasms revealed by a comprehensive screening of 17 tyrosine kinase coding genes.
Aranaz P; Ormazábal C; Hurtado C; Erquiaga I; Calasanz MJ; García-Delgado M; Novo FJ; Vizmanos JL
Cancer Genet Cytogenet; 2010 May; 199(1):1-8. PubMed ID: 20417861
[TBL] [Abstract][Full Text] [Related]
39. Phospho-STAT5 expression pattern with the MPL W515L mutation is similar to that seen in chronic myeloproliferative disorders with JAK2 V617F.
Gibson SE; Schade AE; Szpurka H; Bak B; Maciejewski JP; Hsi ED
Hum Pathol; 2008 Jul; 39(7):1111-4. PubMed ID: 18479730
[TBL] [Abstract][Full Text] [Related]
40. WHO bone marrow features and European clinical, molecular, and pathological (ECMP) criteria for the diagnosis of myeloproliferative disorders.
Michiels JJ; De Raeve H; Hebeda K; Lam KH; Berneman Z; Schroyens W; Schwarz J
Leuk Res; 2007 Aug; 31(8):1031-8. PubMed ID: 17367853
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]